Preventing Young Infant Infections Using Azithromycin in Labour (PreYIAL) Trial

  • STATUS
    Recruiting
  • End date
    May 24, 2022
  • participants needed
    2110
  • sponsor
    Murdoch Childrens Research Institute
Updated on 24 January 2021
antibiotics

Summary

A trial to assess cumulative incidence of skin and soft tissue infections (SSTI) in infants (by three months of age) born to mothers receiving a single-dose of 2 grams of oral azithromycin during labour (or immediately prior to delivery in the case of caesarean section), compared to infants whose mothers received placebo.

Description

PreYIAL is a Phase III, double-blind, randomised, placebo controlled two arm trial of a single 2g dose of azithromycin or placebo, administered to women who have been admitted for delivery of their baby (either following onset of labour or for caesarean section).

The trial includes an estimated 2110 mothers/infant pairs (1055 per arm), with 12 months of follow-up for the mother/infant pair.

A swab-study within the main study involves 940 of the mother/infant pairs enrolled and involves follow-up for bacterial carriage outcomes, for 12 months.These swab-study participants will also be included in assessments of the infant and maternal microbiome.

Details
Condition Bacterial Infection, Bacterial Infections, Bacterial Infections, bacterial disease
Treatment Matching Placebo, Azithromycin 500 mg Oral Tablet x 4
Clinical Study IdentifierNCT03925480
SponsorMurdoch Childrens Research Institute
Last Modified on24 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Pregnant women at least 18 years old intending to deliver at Colonial War Memorial Hospital (CWMH)
Women who have been admitted to CWMH for delivery at the time of eligibility assessment
Women who expect to be available, with their infant, for the duration of the study, and who agree to adhere to all protocol requirements
Women who will have a main place of residence within the Greater Suva area for the follow-up period and within a practical distance of the study site to allow compliance with protocol-required visits and follow-up, including attending follow-up at specified clinics
Women who have provided written informed consent prior to study-related procedures being performed

Exclusion Criteria

Women who have a known macrolide allergy
Women who have taken antibiotics in the week prior to randomisation
A women who is unable or unwilling to provide informed consent for her participation in the trial or the participation of her infant
Women who decide prior to randomisation that they are no longer willing to participate or to have their infant participate
Women who have ever received, or who are anticipated to receive during the study period, any investigational agent other than the study drug
Women who are CWMH, Murdoch Children's Research Institute (MCRI) or study site employees who work directly with study staff, or who are working on the study
Women taking warfarin due to the potential for drug interactions with azithromycin
Women with any cardiac abnormality
Women taking other medications known to prolong the QT interval such as antiarrhythmics; antipsychotic agents; antidepressants; and fluoroquinolones
Women with known electrolyte disturbances: including in cases of hypokalaemia and hypomagnesaemia
Women who will undergo general anaesthetic for delivery
Women carrying a foetus with intrauterine death confirmed before randomisation
Women carrying a foetus with a prognosis unlikely to survive
Women with known HIV infection and/or taking nelfinavir
Women who have participated in the study during a previous pregnancy
Women who have been admitted for management of premature labour who have unruptured membranes (This is a temporary exclusion such that the participant may be assessed for eligibility again in the same or a subsequent admission to CWMH)
Women with renal impairment
Women with hepatic impairment
Women with myasthenia gravis
Women who are taking any ergot medications
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note